NEJM· @NEJM · X·· 3 小时前AI 评分22
AI 导读
GLP-1药物的疗效和受欢迎程度引发了一场开发更强效疗法的竞赛，Sarah H. Schmitz博士在一篇新观点文章中写道。但针对试验中受试者的保护措施可能不足。了解更多：https://nej.md/4hDqlRf
正文
The efficacy and popularity of GLP-1 agents have sparked a race to develop increasingly potent therapies, writes by Sarah H. Schmitz, MD, in a new Perspective. But protections for people enrolled in trials of investigational products may be inadequate. Learn more: https://nej.md/4hDqlRf
来源：NEJM · x.com